Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

@inproceedings{Xue2013GefitinibIC,
  title={Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report},
  author={Xinying Xue and Qingliang Xue and Yuxia Liu and Lei Pan and Kaifei Wang and Lina Zhang and Na Wang and Bing Yang and Jianxin Wang},
  booktitle={Oncology letters},
  year={2013}
}
Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without… CONTINUE READING